Related Experiment Video

Updated: Aug 8, 2026

The Application Of Permanent Middle Cerebral Artery Ligation in the Mouse
08:27

The Application Of Permanent Middle Cerebral Artery Ligation in the Mouse

Published on: July 25, 2011

Angiotensin receptor blockers and cerebral protection in stroke

Christa Thöne-Reineke1, Ulrike M Steckelings, Thomas Unger

  • 1Centre for Cardiovascular Research/Institute for Pharmacology and Toxicology, Charité--Universitätsmedizin Berlin, Germany.

Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension
|April 8, 2006
PubMed

Insights

Angiotensin II type 1 (AT1) receptor blockers (ARBs) effectively reduce stroke incidence. Beyond blood pressure reduction, ARBs offer neuroprotection through AT1 inhibition and AT2 receptor stimulation, proving beneficial in stroke prevention.

Area of Science:

  • Cardiovascular Medicine
  • Neuroscience
  • Pharmacology

Background:

  • Stroke is a major cause of death and disability worldwide.
  • The renin-angiotensin system plays a critical role in cardiovascular and neurological health.
  • Inhibition of the renin-angiotensin system is a recognized strategy for stroke risk reduction.

Purpose of the Study:

  • To summarize the molecular mechanisms underlying the beneficial effects of renin-angiotensin system inhibition in stroke.
  • To emphasize neuroprotective mechanisms beyond blood pressure reduction.
  • To review clinical and animal study data on the efficacy of angiotensin II type 1 (AT1) receptor blockers (ARBs) in stroke.

Main Methods:

  • Review of major clinical trials comparing ARBs with placebo or other antihypertensive drugs.
  • Analysis of animal experimental data elucidating neuroprotective actions of ARBs.
  • Focus on mechanisms involving AT1 receptor antagonism and AT2 receptor stimulation.

Main Results:

  • ARBs demonstrate superiority in stroke prevention compared to other antihypertensive drugs, irrespective of blood pressure changes.
  • Animal studies indicate neuroprotection via AT1 receptor blockade and stimulation of upregulated AT2 receptors in ischemic areas.
  • ARBs provide stroke prevention through mechanisms both dependent and independent of their blood pressure-lowering effects.

Conclusions:

  • ARBs offer significant benefits in stroke prevention through multifaceted mechanisms, including neuroprotection.
  • The dual action on AT1 and AT2 receptors contributes to the efficacy of ARBs in mitigating stroke risk.
  • Further research into the non-hemodynamic effects of ARBs may reveal novel therapeutic strategies for stroke.

More Related Videos

Utilizing a Cranial Window to Visualize the Middle Cerebral Artery During Endothelin-1 Induced Middle Cerebral Artery Occlusion07:43

Utilizing a Cranial Window to Visualize the Middle Cerebral Artery During Endothelin-1 Induced Middle Cerebral Artery Occlusion

Published on: February 22, 2013

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema08:44

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema

Published on: September 1, 2016

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Transient Ischemic Attack l: Introduction01:26

Transient Ischemic Attack l: Introduction

A transient ischemic attack (TIA) is a brief episode of neurological dysfunction caused by a temporary, focal reduction in cerebral blood flow. Although symptoms resemble those of an ischemic stroke, the interruption in perfusion is short-lived and does not cause permanent infarction. TIAs are clinically important because they often serve as early warning events for future stroke.Mechanisms of Transient Cerebral IschemiaTransient cerebral ischemia may arise through several mechanisms. One...